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ABSTRACT
The von Hippel-Lindau tumor suppressor protein
(pVHL) is inactivated in the hereditary cancer
syndrome von Hippel-Lindau disease and in the
majority of sporadic renal carcinomas. pVHL is the
substrate-binding subunit of the CBC
VHL ubiquitin
ligase complex that negatively regulates cell growth
by promoting the degradation of hypoxia-inducible
transcription factor subunits (HIF1/2a). Proteomics-
based identification of novel pVHL substrates
is hampered by their short half-life and low abun-
dancy in mammalian cells. The usefulness of
yeast two-hybrid (Y2H) approaches, on the other
hand, has been limited by the failure of pVHL to
adopt its native structure and by the absence
of prolylhydroxylase activity critical for pVHL sub-
strate recognition. Therefore, we modified the
Y2H system to faithfully reconstitute the physical
interaction between pVHL and its substrates.
Our approach relies on the coexpression of pVHL
with the cofactors Elongin B and Elongin C and with
HIF1/2a prolylhydroxylases. In a proof-of-principle
Y2H screen, we identified the known substrates
HIF1/2a and new candidate substrates including
diacylglycerol kinase iota, demonstrating that
our strategy allows detection of stable interac-
tions between pVHL and otherwise elusive cellular
targets. Additional future applications may
include structure/function analyses of pVHL-
HIF1/2a binding and screens for therapeutically
relevant compounds that either stabilize or disrupt
this interaction.
INTRODUCTION
The yeast two-hybrid (Y2H) system has proved an
invaluable tool for the identiﬁcation of protein–protein
interactions, both in standard laboratory screens and in
high-throughput automated formats (1,2). However,
despite the successful identiﬁcation of thousands of
binding partners from various organisms, the Y2H
approach is subject to certain limitations. For example,
interactions that critically depend on post-translational
modiﬁcations by enzymatic activities absent from yeast
cannot be detected. Furthermore, subunits of heterooligo-
meric complexes are likely to adopt non-native conforma-
tions in the absence of their natural binding partners,
giving rise to biologically irrelevant Y2H interactions.
Both potential problems are illustrated by the human
CBC
VHL E3 ubiquitin ligase complex (3) with its substrate
recognition subunit, the von Hippel-Lindau tumor sup-
pressor protein (pVHL).
CBC
VHL is a heterooligomeric complex comprising the
core subunits Cullin-2, Rbx1/Roc1, Elongin B (ELB) and
Elongin C (ELC), and the pVHL substrate recognition
subunit (3). Key cellular targets of the CBC
VHL E3
ubiquitin ligase activity include the alpha subunit of
hypoxia-inducible transcription factor 1, HIF1a, and
its close homolog, HIF2a, which are important reg-
ulators of angiogenesis, glucose uptake and metabolism,
cell growth and the cell cycle (4–6). Recognition of
HIF1/2a by pVHL requires the post-translational hydro-
xylation of two conserved prolyl residues (P564 and P402
in human HIF-1a) by a new family of prolylhydroxylases
(PHDs) (7–10). Under normoxic conditions, HIF1/2a
is hydroxylated by PHDs, recruited to CBC
VHL by
pVHL, ubiquitylated and rapidly degraded by the
26S proteasome. Conversely, in a hypoxic cellular
Present addresses:
Claudia Bex, Department of Biological Sciences, Imperial College London, Imperial College Road, London SW7 2AZ, UK.
Katja Knauth, Institute of Biochemistry, Swiss Federal Institute of Technology Zurich, Schafmattstrasse 18, CH-8093 Zurich, Switzerland.
*To whom correspondence should be addressed. Tel: +49 89 8578 3050; Fax: +49 89 8578 3022; Email: buchberg@biochem.mpg.de
 2007 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.environment lacking the PHD substrate, molecular
oxygen, HIF1/2a is not recognized by pVHL and thus
stable, leading to the expression of HIF target genes (4–6).
Mutational inactivation of pVHL causes the constitutive
expression of HIF target genes even under normoxic
conditions, which has been shown to be a key tumorigenic
event in the hereditary cancer syndrome von Hippel-
Lindau disease (11–13).
The identiﬁcation of CBC
VHL targets other than
HIF1/2a has proven diﬃcult in the past. Proteomics
strategies relying on aﬃnity puriﬁcation schemes and
subsequent mass spectrometric identiﬁcation are compli-
cated by the potential low abundance and short half-life of
candidate proteins in mammalian cells. Y2H screens, in
contrast, typically depend much less on the physiological
abundance and half-life of interactors. In particular,
Saccharomyces cerevisiae does not possess orthologs of
Cullin-2, ELB and ELC, so that pVHL substrates are not
subject to ubiquitylation by the CBC
VHL ubiquitin ligase
complex and subsequent proteasomal degradation.
Consequently, it should, in principle, be possible to
detect stable Y2H interactions of pVHL with substrates
such as HIF1/2a, which are extremely short-lived and of
low abundance in mammalian cells. However, Y2H
screens using pVHL as bait are impeded by two major
limitations: ﬁrst, pVHL is unable to adopt its native
conformation in the absence of the CBC
VHL subunits
ELB and ELC (14,15). In contrast, pVHL in the context
of the ternary pVHL–ELB–ELC (VCB) subcomplex
of CBC
VHL possesses its native, stable fold and is
amenable to structural and biochemical studies (14,16).
In particular, the pVHL-binding site for HIF1/2a, and
presumably other cellular substrates, is only formed in
presence of ELB and ELC (17,18). Second, yeast does not
possess PHD homologs, precluding the detection of
hydroxyprolyl-mediated Y2H interactions.
Here, we describe a modiﬁed Y2H system for the
detection of pVHL–substrate interactions that relies on
the coexpression of pVHL with the cofactors ELB and
ELC and with PHDs. We show that this system is able to
faithfully recapitulate HIF1a binding to pVHL in yeast.
Moreover, we report the identiﬁcation of the known
substrates HIF1/2a, along with new candidate substrates,
in a proof-of-principle library screen, thus demonstrating
the strength of the system in detecting even rare pVHL–
substrate interactions.
MATERIALS AND METHODS
Yeaststrains and media
The S. cerevisiae reporter strains CG1945 (MATa, ura3-
52, his3-200, lys2-801, ade2-101, trp1-901, leu2-3,112,
gal4-542, gal80-538, cyh
r2, LYS2::GAL1UAS-GAL1TATA-
HIS3, URA3::GAL417mers(X3)-CYC1TATA-lacZ) and
CG1945BC (CG1945, ADE2::YIpDCE1-ElonginB-
ElonginC) were described previously (19). Cells were
grown in YPD medium (1% yeast extract, 2%
peptone and 2% glucose), or in SC medium (0.67%
yeast nitrogen base without amino acids, 2% glucose)
supplemented with an amino acid mix lacking the
indicated amino acids for selection and induction of the
PMET25 promoter.
Plasmids
Plasmids used in this study are listed in Table 1. Bait
plasmids were constructed using standard procedures
by cloning the coding sequences for the short isoform
of human pVHL (codons 54–213) and for human full-
length PHD1, a PHD2 variant lacking residues 76–177
(10), or full-length PHD3 into multiple cloning sites 1 and
2, respectively, of pBridge (Clontech). Prey plasmids
were constructed by cloning the coding sequences of
full-length human HIF1a or full-length and truncated
human DGKi into pACT2 (Clontech). Mammalian
pVHL expression plasmids were constructed by cloning
the coding sequences for the long (codons 1–213)
and short (codons 54–213) isoforms, respectively,
of human pVHL into pCMV-Tag2B (Stratagene).
Construction details are available from the authors upon
request. The mammalian expression plasmid pCMV-HA-
DGKi (20) was a gift of S. Prescott. pACT2-HIF1aPPAG,
pACT2-DGKi1-1065PPAA and pACT2-DGKi879-
1065PA were generated by site-directed mutagenesis of
the corresponding wild-type plasmids using the
QuikChangeXL kit (Stratagene) according to the manu-
facturer’s instructions. All inserts were fully sequenced.
Directed two-hybrid interactions
For the initial characterization of the two-hybrid system
and for the veriﬁcation of screening results, yeast cells were
transformed simultaneously with bait and prey plasmids
according to Knop et al. (21) and plated onto plates
lacking leucine, tryptophane and methionine (SC-LWM).
After 3 days, several transformants were picked with a
sterile toothpick and resuspended in sterile water. Cell
numbers were adjusted to an OD600nm of 0.2, and 5mlo f
the cell suspension were spotted onto selective plates as
indicated. Interactions were evaluated after 3 days.
Y2H screen
CG1945BC yeast cells carrying the bait plasmid pBridge-
pVHL/PHD3 were transformed with a human testis
cDNA library in pACT2 (Clontech) according to the
protocol for high transformation eﬃciency by Gietz and
Woods (22). A total of 1.5 10
7 transformants were
plated onto plates lacking leucine, tryptophane, methio-
nine and histidine (SC-LWMH) and containing 5mM
3-aminotriazol (3-AT). Colonies appearing after 3 days
were replica plated onto SC-LWMH plates containing 5
or 25mM 3-AT and incubated for 5 days. Subsequently,
5-bromo-4-chloro-3-indoyl b-D-galactoside (XGal)
colony-lift ﬁlter assays were performed according to the
Clontech Yeast Protocols Handbook. Prey plasmids from
colonies growing in the presence of 5 and 25mM 3-AT
and scoring positive in XGal colony-lift ﬁlter assays were
isolated and re-transformed together with pBridge-pVHL/
PHD3 to verify the interaction, or with pBridge-empty/
PHD3 to identify auto-activating library plasmids.
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Yeast patches growing on SC-LWM control plates were
picked and dissolved in sterile water, diluted to identical
OD600nm values and further processed for western blot
analysis according to Knop et al. (21). Expression levels
were detected with antibodies against pVHL (Ig32;
Pharmingen), HIF1a, PHD1, PHD2, PHD3 (all Novus
Biologicals) and Gal4 transactivation domain (sc-1663;
Santa Cruz).
Immunoprecipitation
HEK293T cells grown in DMEM, 10% FCS, 100U/ml
penicillin, 100mg/ml streptomycin in 10cm cell culture
dishes were co-transfected with mammalian expression
plasmids pCMV-2B-VHL and pCMV-HA-DGKi using
the calcium phosphate method. Forty-eight hours after
transfection, cells were harvested, washed with buﬀer ECB
(50mM Tris–HCl, 150mM NaCl, 1mM EDTA, pH 7.9),
and resuspended in lysis buﬀer (ECB supplemented with
0.25% NP-40, 1mM DTT, 25mM MG132, 6mg/ml
antipain, 4.3mg/ml leupeptin, 4.5mg/ml aprotinin, 5mg/
ml trypsin inhibitor, 5mg/ml pepstatin, 6mg/ml chymo-
statin, 10mM NEM). After 15min incubation on ice,
lysates were cleared by centrifugation (15min, 20000g),
and the protein concentrations of the supernatants were
adjusted with lysis buﬀer. FLAG-tagged pVHL was
immunoprecipitated by overnight incubation with 35ml
of FLAG-M2 beads (Sigma), followed by three wash steps
with ECB containing 0.25% NP-40 and 1mM DTT.
Bound proteins were analyzed by western blots using anti-
FLAG antibody (M2, Sigma) and a polyclonal rabbit
antibody raised in-house against a recombinantly
expressed, C-terminal fragment (amino acid residues
748–1065) of DGKi.
RESULTS
Reconstitution ofpVHL substrate interactions inaY2H
system
Due to serious doubts about the usefulness of free,
presumably non-native pVHL as bait in standard Y2H
screens, our aim was to establish a system that was able to
identify selectively, or at least preferentially, interactors
and bona ﬁde substrates of native pVHL in the context of
the stable, ternary VCB complex. To that end, we relied
on a previously established reporter yeast strain constitu-
tively expressing ELB and ELC, CG1945BC (19). This
strain was transformed with a plasmid derived from the
pBridge vector that allows simultaneous expression of the
bait pVHL fused to the Gal4 DNA-binding domain (BD)
with one of the three human PHDs (Figure 1a). To test the
functionality of this system, we used a prey plasmid
expressing HIF1a fused to the Gal4 activation domain
(AD) (Figure 1a). According to the rationale of the system
(Figure 1b), proline residues 402 and/or 564 of HIF1a
should be hydroxylated by the PHDs. The prolyl
hydroxylation enables pVHL to bind HIF1a, provided
that pVHL is stabilized in its native conformation by ELB
and ELC. This hydroxyprolyl-dependent interaction
between bait and prey should direct the quartenary
BD-pVHL/ELB/ELC/AD-HIF1a complex to Gal4
binding sites upstream of the HIS3 and lacZ reporter
genes via the BD fused to pVHL, thus inducing the
activation of reporter gene expression by the AD fused
Table 1. Plasmids used in this study
Plasmid name Vector Insert(s) Reference
pACT2 pACT2 None Clontech
pACT2-HIF1a pACT2 Human full-length HIF1a This study
pACT2-HIF1aPPAG pACT2 Human full-length HIF1a P402A/P564G This study
pACT2-DGKi1-1065 pACT2 Human full-length DGKi This study
pACT2-DGKi1-878 pACT2 Human DGKi aa 1–878 This study
pACT2-DGKi1-667 pACT2 Human DGKi aa 1–667 This study
pACT2-DGKi879-1065 pACT2 Human DGKi aa 879–1065 This study
pACT2-DGKi668-1065 pACT2 Human DGKi aa 668–1065 This study
pACT2-DGKi1-1065PPAA pACT2 Human full-length DGKi P147A/P903A This study
pACT2-DGKi879-1065PA pACT2 Human DGKi aa 879–1065 P147A/P903A This study
pBridge-pVHL/empty pBridge Human pVHL aa 54–213 (MCS 1) This study
pBridge-pVHL/PHD1 pBridge Human pVHL aa 54–213 (MCS 1) This study
Human full-length PHD1 (MCS 2)
pBridge-pVHL/PHD2 pBridge Human pVHL aa 54–213 (MCS 1) This study
Human PHD276–177 (MCS 2)
pBridge-pVHL/PHD3 pBridge Human pVHL aa 54–213 (MCS 1) This study
Human full-length PHD3 (MCS 2)
pBridge-empty/PHD1 pBridge None (MCS 1) This study
Human full-length PHD1 (MCS 2)
pBridge-empty/PHD2 pBridge None (MCS 1) This study
Human PHD276–177 (MCS 2)
pBridge-empty/PHD3 pBridge None (MCS 1) This study
Human full-length PHD3 (MCS 2)
pCMV2B-pVHL19 pCMV2B Human pVHL aa 54–213 This study
pCMV2B-pVHL30 pCMV2B Human pVHL aa 1–213 This study
pcDNA-HA-DGKi pCMV-HA Human full length DGKi Ref. 20
MCS, multiple cloning site; pVHL, von Hippel-Lindau protein; PHD, prolyl hydroxylase; DGK, diacylglycerol kinase.
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ability of the reporter yeast strain to grow onmedia lacking
histidine, and by the blue staining of colonies in XGal ﬁlter
assays.
Using this system, we observed a robust interaction
between pVHL and HIF1a that was strictly dependent on
the presence of one of the three PHDs (Figure 2a).
Consistent with this requirement for a PHD, no interac-
tion was detected between pVHL and a HIF1a variant
lacking the critical PHD target residues Pro402 and
Pro564, HIF1aPPAG. Furthermore, no interaction
could be detected in a control reporter strain lacking
ELB and ELC, indicating that the two-hybrid interaction
required the native conformation of pVHL in the context
of the VCB complex. Importantly, western blot analysis
demonstrated that the lack of the two-hybrid interaction
in the negative controls was not the consequence of
reduced expression levels of pVHL, the PHDs or HIF1a
PPAG (Figure 2b–f). Together, these results indicate that
the observed two-hybrid interaction between pVHL and
HIF1a faithfully recapitulates the biologically relevant
interaction found in human cells.
Screening fornovel pVHL interactors
While the role of pVHL in the regulation of HIF1/2a is
well understood (23–25) and a number of novel cellular
functions for pVHL have emerged recently (26–28), the
search for additional substrates of the CBC
VHL ubiquitin
ligase complex remains a key objective in elucidating the
pathology of von Hippel-Lindau disease. The existence of
three diﬀerently regulated PHD isoforms exhibiting
diﬀerential activities towards HIF1/2a (7,8,29) and the
apparently intact regulation of HIF1/2a in some subtypes
of von Hippel-Lindau disease (30,31) suggests that
additional cellular targets of CBC
VHL exist. Our Y2H
system should principally be able to identify such targets.
After having successfully established the system in
directed interaction assays, we thus tested its potential
by performing a Y2H screen of a human testis cDNA
library. We used the pBridge-pVHL/PHD3 bait plasmid
because PHD3 appears to possess the least stringent
substrate speciﬁcity of the three human PHDs (32) and is
localized in both nucleus and cytoplasm in mammalian
cells (33). We screened 1.5 10
7 transformants on
SC-LWMH plates containing 5mM 3-aminotriazol,
replica plated onto plates containing 5 or 25mM
3-aminotriazol, and performed XGal ﬁlter lift assays
from these plates. Prey plasmids from colonies growing
on 5 and 25mM 3-aminotriazol and scoring positive in the
XGal assay were isolated and re-transformed into the
reporter strain either together with the bait plasmid
pBridge-pVHL/PHD3 toverifythetwo-hybridinteraction,
orwithpBridge-empty/PHD3toidentifybait-independent,
auto-activating library plasmids. About 100 true-positive
interactors were further tested for two-hybrid interactions
in the absence of PHD3 or ELB/ELC, respectively. Among
the true-positive interactors, multiple full-length cDNAs
of ELC and ELB were identiﬁed that mediated a
PHD3-independent interaction with pVHL, as expected
(Table 2). Importantly, we identiﬁed several cDNAs
encoding fragments of HIF1a and HIF2a, thus providing
convincing proof-of-principle for the usefulness of our
system in Y2H screens. All HIF1/2a fragments spanned
one of the two critical prolyl residues and mediated an
interaction with pVHL that was entirely dependent on
PHD3, ELB and ELC (Table 2 and data not shown), again
illustrating the unique speciﬁcity of the system.
Besides these known interactors, we identiﬁed eight
new binding partners that interacted with pVHL in a
PHD3- and ELB/ELC-dependent manner, some of them
possessing variants of the LxxLAP target motif for PHDs
found in HIF1/2a (Table 2 and data not shown). In
summary, the Y2H screen led to the identiﬁcation of both
known and potential novel substrates of pVHL.
A novel,PHD-dependent two-hybrid interactor ofpVHL
A particularly interesting new interactor is diacylglycer-
olkinase iota (DGKi), a member of an enzyme family
PPGK1 PPGK1
ELB ELC
chr. XV
Fe2+, O2
PHD
growth on SC-His
blue colonies
Pro
AD
HIF1α HO-Pro
AD
HIF1α
AD BD
reporter gene GAL
HO-Pro HIF1α pVHL
ELB
ELC
BD
pVHL ELC
ELB
(a)
(b)
Gal4-BD
pVHL
PHD
TRP1
pBridge-
pVHL/PHD
PADH1
PMET25
pACT2-
HIF1α
PADH1
Gal4-AD
HIF1α
LEU2
Figure 1. Yeast two-hybrid system for the detection of pVHL–substrate
interactions. (a) Essential elements of the system. The BD-pVHL bait
and AD-HIF1a prey fusions are expressed from the pBridge and
pACT2 vectors under the control of the constitutive PADH1 promoter.
The pBridge vector in addition allows for the expression of PHD1, 2
or 3 under the control of the PMET25 promoter, which is induced in
the absence of methionine. The yeast reporter strain CG1945BC is a
derivative of CG1945 expressing ELB and ELC under the control of
the constitutive PPGK1 promoter from chromosome XV next to the
ADE2 locus (19). (b) Schematic representation of reporter gene
activation by the PHD-, ELB-, ELC-dependent interaction between
BD-pVHL and AD-HIF1a. Pro, HO-Pro; unmodiﬁed and hydroxy-
lated form, respectively, of PHD target prolyl residues.
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and phosphatidic acid levels (20,34). DGKi is predomi-
nantly expressed in brain and retina, two tissues that are
most frequently aﬀected in VHL disease. Intriguingly,
DGKi contains two LxxLAP motifs at residues Pro147
and Pro903 that are potential targets for PHD-catalyzed
prolyl hydroxylation (Figure 3), one of which was present
in the original isolate from the two-hybrid screen
(DGKi668–1065; Figure 4a and Table 2).
We thus further characterized the two-hybrid interac-
tion between DGKi and pVHL. To map the region of
pVHL binding more precisely, we generated diﬀerent
truncated versions of DGKi fused to the AD (Figure 4a).
While full-length DGKi1-1065 interacted with pVHL in a
PHD3- and ELB/ELC-dependent manner (Figure 4b),
C-terminally truncated variants lacking the LxxLAP motif
at Pro903 failed to interact, demonstrating that the
C-terminal LxxLAP motif is required for the interaction
with pVHL. Consistently, the C-terminal fragment
DGKi879-1065 including the C-terminal LxxLAP motif
was suﬃcient for the pVHL interaction. Next, we directly
tested the importance of the LxxLAP motif for
pVHL interaction by mutating the critical prolyl residue,
either alone (DGKi879-1065PA) or in concert with
the N-terminal LxxLAP motif (DGKi1-1065PPAA).
Importantly, neither of the two DGKi variants interacted
with pVHL (Figure 4b), strongly suggesting that the two-
hybrid interaction depends on the PHD3-catalyzed prolyl
hydroxylation of residue Pro903. The expression levels of
these mutant prey constructs were found to be very similar
to those of the respective wild-type constructs (Figure 4c).
Furthermore, we analyzed the PHD speciﬁcity of the
interaction and found that full-length DGKi interacted
strongly with pVHL in the presence of PHD3, while only a
very weak interaction was detectable in the presence of
PHD1 or PHD2 (Figure 5). This result is consistent with
the possibility that PHD3 has evolved to recognize a
broader range of substrates than the PHD1 and PHD2
isoenzymes (32).
Finally, we wished to test whether pVHL and DGKi
also interact in human cells. To this end, 293T cells were
transiently transfected with expression plasmids for full-
length DGKi and the long and short isoforms of pVHL,
respectively. DGKi was eﬃciently co-immunoprecipitated
with both pVHL isoforms, but not in the negative control
Table 2. pVHL interactors identiﬁed in the yeast two-hybrid screen
Prey Longest fragment
found
a
Number
of hits
PHD3
requirement
b
LxxLAP
motif
c
Elongin C aa 4–112 (CT) 26 No No
Elongin B aa 2–118 (CT) 10 No No
HIF1a aa 232–439, 6 Yes Yes
aa 537–777
HIF2a aa 331–537 1 Yes Yes
DGKi aa 668–910 2 Yes Yes
KIF2C aa 558–681 1 Yes Yes
THO1 aa 578–657 (CT) 1 Yes (Yes)
Calpain 7 aa 536–679 8 Yes (Yes)
YY1AP1 aa 604–739 (CT) 20 Yes No
RBP-MS/type 3 aa 23–201 1 Yes No
RB1CC1 aa 1407–1594 (CT) 1 Yes No
FKBP38 aa 97–344 1 Yes No
aAmino acid residues as determined by sequencing of the prey plasmid
insert from the 50 end; (CT), residue number denotes the authentic
C-terminus of the protein; otherwise, the second residue number
indicates the end of the sequenced region, not the 30 end of the prey
plasmid insert. Because an oligo(dT)-primed cDNA library was used,
most inserts include the authentic 30 end of the coding sequence and
some 30 untranslated region of the cDNA.
bAs tested by co-transformation of the prey plasmid with pBridge-
pVHL/empty.
cBrackets indicate presence of divergent motifs that may still be
recognized by PHDs (32).
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Figure 2. Yeast two-hybrid interaction between pVHL and HIF1a.
(a) CG1945BC (+ELB/C) or CG1945 (–ELB/C) yeast cells trans-
formed with the indicated combinations of bait (pBridge-) and prey
(pACT2-) plasmids were diluted to an OD600nm of 0.2 and spotted
on SC-Leu-Trp-Met (—LWM) control plates or SC-Leu-Trp-Met-His
(—LWMH) reporter plates containing 1mM 3-aminotriazole (3-AT).
(b)–(f) Expression levels of components of the yeast two-hybrid system.
Yeast cells were directly taken from the SC-Leu-Trp-Met control plates
shown in (a), dissolved in sterile water and diluted to identical OD600nm
values. Protein expression levels were determined by western blots
(WB) using antibodies against pVHL (b), HIF1a (c), PHD1 (d), PHD2
(e) and PHD3 (f). Shown are representative sets of samples taken from
CG1945BC cells expressing the indicated pBridge (b, d–f) and pACT2
(c) constructs. Expression levels were independent of the presence of
ELB/ELC and of speciﬁc combinations of bait and prey plasmids, as
tested in random samples obtained from several diﬀerent yeast colonies
on the SC-Leu-Trp-Met control plates (data not shown). In (c), an
asterisk indicates the HIF1a band.
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two-hybrid interactor DGKi physically associates with
pVHL in human cells, further strengthening the validity of
our two-hybrid approach.
DISCUSSION
Mutations in the von Hippel-Lindau tumor suppressor
gene (VHL) are the basis of the familial tumor syndrome
von Hippel-Lindau disease and the majority of sporadic
renal clear cell carcinomas (35–37). Mutational inactiva-
tion of pVHL, the substrate-binding subunit of the
CBC
VHL ubiquitin ligase complex, leads to the constitu-
tive stabilization of the key cellular substrate, HIF1/2a,
and presumably other cellular targets. However, system-
atic approaches for the identiﬁcation of CBC
VHL sub-
strates have so far been largely unsuccessful, despite the
great medical relevance.
We have designed and established a powerful adaptation
of the Y2H system that allows to screen for novel targets of
the pVHL tumor suppressor protein. Our strategy relies on
the reconstitution of the VCB complex in yeast (19), which
enables pVHL to adopt its native 3D conformation, and on
the coexpression of the substrate modifying enzymes of the
PHD family. In a novel combination, our system introduces
both a new enzymatic activity and structural cofactors into
the yeast background to screen for protein–protein interac-
tions requiring a complex interplay of post-translational
modiﬁcation and physical interaction. This combination
allows for the rigorous testing of positive clones by omitting
either the enzymatic activity or the cofactors. Our strategy is
not only useful in order to eliminate a large number of false-
positive interactors resulting from interaction with non-
native bait, but also, more importantly, enables for the ﬁrst
time to distinguish between potential substrates and
regulatory or scaﬀolding proteins. This is illustrated by
our proof-of-principle library screen, which identiﬁed the
known pVHL substrates HIF1/2a as strictly PHD-depen-
dent interactors. To our knowledge, this is the ﬁrst
identiﬁcation of HIF1/2a in a Y2H screen and, in fact, in
any approach aiming at the identiﬁcation of pVHL
substrates. Previous standard Y2H screens in the absence
of ELB, ELC and PHDs had not only failed to identify
HIF1/2a, but also often led to the isolation of molecular
chaperones and enzymes of the protein degradation
machinery, suggesting that most of these proteins bound
to non-native pVHL (27,38–40). Of note, we did not identify
any chaperone or notorious false-positive Y2H interactor in
our screen (Table 2), underlining its superior design with
respect to the integrity of the native 3D structure of pVHL.
Together, our results demonstrate that our adaptation of
the Y2H system can successfully be used to screen for
pVHL substrates of even extremely low cellular abundance
such as HIF1/2a, as long as their transcripts are represented
in a cDNA library. This is a signiﬁcant advantage over
proteomics strategies based on aﬃnity puriﬁcation, which
often fail to identify low abundance binding partners
because of insuﬃcient sensitivity of detection and/or high
background from abundant proteins.
Our system sets the precedence for a method that can
easily be adapted to other heterooligomeric ubiquitin
ligases, in particular cullin-based complexes with their
diverse substrate recognition requirements (3). Prime
examples of high medical importance are Cullin-5 com-
plexes which, like CBC
VHL, contain ELB and ELC as core
subunits, but use members from the SOCS (suppressor of
cytokine signaling) box superfamily as substrate-binding
subunits (3,41,42). Some SOCS box proteins like CIS-1,
SOCS-1, SOCS-2 and SOCS-3 recruit phosphotyrosine-
modiﬁed substrates via SH2 domains and are important
regulators of immune responses and other cytokine-
regulated processes (43). Remarkably, these SOCS pro-
teins exhibit high substrate speciﬁcity despite similarities
in the composition of their SH2 domains (44), and regions
outside the SH2 domains also contribute to substrate
binding (45,46). Replacing the bait vector of our system
with one that encodes SOCS proteins as baits together
with the critical tyrosine kinases (which are absent from
yeast) should be a straightforward adaptation to study the
exact binding requirements of SOCS proteins and to
screen for novel substrates. SOCS proteins with other
functional domains are less well understood, but recent
ﬁndings suggest that an ankyrin domain-containing family
member, ASB4, is modiﬁed by an asparagine hydroxylase
called FIH (factor inhibiting HIF) (47), an oxygen-
converting enzyme related to the PHDs which was ﬁrst
identiﬁed as a negative regulator of HIF transcriptional
activity (48). ASB4 plays an important role in vascular
diﬀerentiation and has been proposed to recruit yet
unknown substrates to a Cullin-5 ubiquitin ligase
complex in an asparagine hydroxylation-dependent
manner (47). Consequently, employing a bait vector
encoding ASB4 as bait together with FIH in our Y2H
system could proof a successful adaptation to screen for
ASB4 substrates.
Our Y2H screen led to the identiﬁcation of several
potential novel CBC
VHL substrates that showed a
dependency on PHD and ELB/ELC, some containing an
LxxLAP motif for recognition by PHDs similar to the
one found in HIF1/2a (Table 2). One such candidate
exhibiting interaction characteristics resembling those of
HIF1/2a is DGKi. We showed that the Y2H interaction
between pVHL and DGKi requires its C-terminal
LxxLAP motif, which is not conserved among other
DGK isoforms. Intriguingly, and in contrast to other
DGK isoforms, which show a rather broad tissue
distribution, expression of DGKi appears to be strongest
in brain and retina (20), which are both frequently aﬀected
in pVHL disease. This correlation might hint to a
HIF1α 392-414 KEPDA     LTLLAP      AAGDTIISLDFG
HIF2α 395-417 EEPEE     LAQLAP      TPGDAIISLDFG
DGKι 141-148     G     LQHLAP      A
HIF1α 551-585 STQDT--DLD     LEMLAP      YIPMD-DDFQLRSF-DQLSPLES
HIF2α 516-554 STQTDFNELD     LETLAP      YIPMDGEDFQLSPICPEERLLAE
DGKι 894-921 SDS------G     LGMIAP      YY----EDSDLKDL-SHSRVLQS
Figure 3. DGKi possesses two LxxLAP motifs. Sequence alignments of
the N-terminal (top) and C-terminal (bottom) PHD recognition motifs
found in HIF1a, HIF2a and DGKi. The LxxLAP consensus motif is
underlined, with the target prolyl residue in bold.
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and DGKi, a possibility that is currently addressed in our
laboratory.
In addition to the identiﬁcation of further pVHL targets
in Y2H screens using various cDNA libraries, our system
is well suited to perform detailed analyses of the physical
interaction between pVHL and full-length HIF1/2a. This
should be a welcome addition to the currently available
experimental approaches, which are limited to qualitative
pull-down experiments and quantitative, but laborious
biochemical measurements. The possibility to evaluate
the Y2H interaction between pVHL and HIF1/2a in
liquid culture using colorimetric b-galactosidase activity
assays based on ortho-nitrophenyl-b-D-galactopyranoside
(ONPG) even provides the opportunity for semi-
quantitative analyses. Additionally, since the PHDs are
active in yeast, their speciﬁcity and mechanism of HIF1/2a
regulation could also be further characterized by muta-
tional analysis, using the pVHL-HIF1/2a interaction as
a functional read-out.
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Figure 4. Two-hybrid interaction between pVHL and the candidate substrate, DGKi.( a) Schematic representation of full-length DGKi and the
constructs used in two-hybrid assays. Key domains and sequence motifs are indicated at the top, and the two LxxLAP motifs are indicated at the bottom
of the bars. (b) ELB-, ELC- and LxxLAP motif-dependent interaction between pVHL and DGKi. Two-hybrid interactions between BD-pVHL and the
indicated AD-DGKi and AD-HIF1a constructs were assayed as in Figure 2a. (c) Expression levels of AD-DGKi constructs. Protein samples were
prepared as in Figure 2b–f. Shown are representative samples taken from CG1945BC cells expressing the indicated DGKi constructs. Expression levels
were determined by western blot (WB) using Gal4-AD antibody. Asterisks indicate bands of the diﬀerent DGKi constructs.
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screens for therapeutically relevant chemical compounds
that speciﬁcally alter the interaction between pVHL and
HIF1/2a (4,49,50). For example, drugs that rescue or
improve the binding of HIF1/2a to mutant pVHL could
lead to improved down-regulation of HIF1/2a in patients
carrying certain partial loss-of-function VHL alleles.
Conversely, compounds interrupting the physiological
interaction between pVHL and HIF1/2a that occurs
under hypoxic conditions might be useful in the treatment
of acute ischemia. Such compounds may conveniently be
screened for in liquid culture high-throughput formats
using ONPG b-galactosidase activity assays. In the past,
Y2H-based approaches have successfully been used to
identify small-molecule inhibitors of protein–protein
interactions, for example a modulator of neuronal
N-type calcium channels from a library of 156000 small
molecules (51), and an inhibitor of TGFb receptor
signaling from a library of 23000 compounds (52).
We found that Co
2+, a known inhibitor of the interaction
between pVHL and HIF1/2a in mammalian cells (53,54),
is also eﬀective in the context of our Y2H system
(Supplementary Figure S1), which further underlines the
feasibility of small molecule screens using this system.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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